APO Research, Inc.
Talk to an analyst

APO RESEARCH · REPORT

Eosinophilic Esophagitis Drug

Eosinophilic esophagitis (EoE, also spelled eosinophilic oesophagitis), also known as allergic oesophagitis, is an allergic inflammatory condition of the esophagus that involves eosinophils, a type of white blood cell. Symptoms are swallowing difficulty, food impaction, vomiting, and heartburn.

Explore the product
View pricing & licenses

Product & engineering

Understand the product.

Eosinophilic esophagitis (EoE, also spelled eosinophilic oesophagitis), also known as allergic oesophagitis, is an allergic inflammatory condition of the esophagus that involves eosinophils, a type of white blood cell. Symptoms are swallowing difficulty, food impaction, vomiting, and heartburn.

Eosinophilic esophagitis was first described in children but also occurs in adults. The condition is not well understood, but food allergy may play a significant role. The treatment may consist of removal of known or suspected triggers and medication to suppress the immune response.

This report studies the eosinophilic esophagitis drug market.

Selected research

Market Structure

Global Eosinophilic Esophagitis Drug Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032

Report ID 173988720325 December 2025193 pages

Choose your research edition.

Industry ResearchEosinophilic Esophagitis Drug Industry Research Report 2026122 pages · $2,950 USDIndustry Growth & TrendsGlobal Eosinophilic Esophagitis Drug Industry Growth and Trends Forecast to 2032104 pages · $3,450 USDMarket StructureGlobal Eosinophilic Esophagitis Drug Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032193 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Eosinophilic Esophagitis Drug Market Outlook and Growth Opportunities 2026194 pages · $4,250 USDMarket Analysis & ForecastGlobal Eosinophilic Esophagitis Drug Market Analysis and Forecast 2026-2032199 pages · $4,950 USD

Market perspective

Eosinophilic esophagitis (EoE, also spelled eosinophilic oesophagitis), also known as allergic oesophagitis, is an allergic inflammatory condition of the esophagus that involves eosinophils, a type of white blood cell. Symptoms are swallowing difficulty, food impaction, vomiting, and heartburn.

Eosinophilic esophagitis was first described in children but also occurs in adults. The condition is not well understood, but food allergy may play a significant role. The treatment may consist of removal of known or suspected triggers and medication to suppress the immune response.

This report studies the eosinophilic esophagitis drug market.

Read the full market overview

AstraZeneca, GSK and Bayer are the leading producers of eosinophilic esophagitis drug, which together account for about 80% of the market.

North America is the leading region, accounting for more than 30% of the market, followed by Europe at nearly 30%.

This report provides an overview of the global Eosinophilic Esophagitis Drug market in terms of sales, revenue, and price, analyzing global market trends using historical revenue and sales data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Eosinophilic Esophagitis Drug and sales in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Eosinophilic Esophagitis Drug sales, revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

In addition, the report analyzes segment data by Type and Application—covering sales, revenue, and price—for 2021-2032, and evaluates and forecasts the Eosinophilic Esophagitis Drug market size, projected growth trends, production technologies, key applications, and end-use industries.

Eosinophilic Esophagitis Drug Segment by Company

AstraZeneca

GSK

Bayer

Adare Pharmaceuticals

DBV Technologies

Dr. Falk Pharma

Quorum Innovations

Takeda

Calypso

Celgene

Regeneron

Eosinophilic Esophagitis Drug Segment by Type

Budesonide

Fluticasone

Others

Eosinophilic Esophagitis Drug Segment by Application

Hospitals

Clinics

Drugstore

Eosinophilic Esophagitis Drug Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global status and future forecast, involving, production, value, consumption, growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, capacity, production, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify significant trends, drivers, influence factors in global and regions.

6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Eosinophilic Esophagitis Drug market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Eosinophilic Esophagitis Drug and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Eosinophilic Esophagitis Drug.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Provides an overview of the Eosinophilic Esophagitis Drug market, including product definition, global market growth prospects, market size, sales, and average price forecasts (2021-2032).

Chapter 2: Provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Detailed analysis of Eosinophilic Esophagitis Drug manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales of Eosinophilic Esophagitis Drug in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.

Chapter 7: Revenue of Eosinophilic Esophagitis Drug in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 10: Concluding Insights of the report

More report detail

Tables and figures
List of Tables Table 1. Eosinophilic Esophagitis Drug Industry Trends Table 2. Eosinophilic Esophagitis Drug Industry Drivers Table 3. Eosinophilic Esophagitis Drug Industry Opportunities and Challenges Table 4. Eosinophilic Esophagitis Drug Industry Restraints Table 5. Global Eosinophilic Esophagitis Drug Revenue by Manufacturers (US$ Million) & (2021-2026) Table 6. Global Eosinophilic Esophagitis Drug Revenue Market Share by Manufacturers (2021-2026) Table 7. Global Eosinophilic Esophagitis Drug Sales by Manufacturers (K Units) & (2021-2026) Table 8. Global Eosinophilic Esophagitis Drug Sales Market Share by Manufacturers Table 9. Global Eosinophilic Esophagitis Drug Average Sales Price (USD/Unit) of Manufacturers (2021-2026) Table 10. Global Eosinophilic Esophagitis Drug Industry Manufacturers Ranking, 2024 VS 2025 VS 2026 Table 11. Global Eosinophilic Esophagitis Drug Key Manufacturers Manufacturing Sites & Headquarters Table 12. Global Eosinophilic Esophagitis Drug Manufacturers, Product Type & Application Table 13. Global Eosinophilic Esophagitis Drug Manufacturers Establishment Date Table 14. Global Manufacturers Market Concentration Ratio (CR5 and HHI) Table 15. Global Eosinophilic Esophagitis Drug by Manufacturers Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue of 2025) Table 16. Major Manufacturers of Budesonide Table 17. Major Manufacturers of Fluticasone Table 18. Major Manufacturers of Others Table 19. Global Eosinophilic Esophagitis Drug Sales by Type 2021 VS 2025 VS 2032 (K Units) Table 20. Global Eosinophilic Esophagitis Drug Sales by Type (2021-2026) & (K Units) Table 21. Global Eosinophilic Esophagitis Drug Sales by Type (2027-2032) & (K Units) Table 22. Global Eosinophilic Esophagitis Drug Sales Market Share by Type (2021-2026) Table 23. Global Eosinophilic Esophagitis Drug Sales Market Share by Type (2027-2032) Table 24. Global Eosinophilic Esophagitis Drug Revenue by Type 2021 VS 2025 VS 2032 (K Units) Table 25. Global Eosinophilic Esophagitis Drug Revenue by Type (2021-2026) & (K Units) Table 26. Global Eosinophilic Esophagitis Drug Revenue by Type (2027-2032) & (K Units) Table 27. Global Eosinophilic Esophagitis Drug Revenue Market Share by Type (2021-2026) Table 28. Global Eosinophilic Esophagitis Drug Revenue Market Share by Type (2027-2032) Table 29. Major Manufacturers of Hospitals Table 30. Major Manufacturers of Clinics Table 31. Major Manufacturers of Drugstore Table 32. Global Eosinophilic Esophagitis Drug Sales by Application 2021 VS 2025 VS 2032 (K Units) Table 33. Global Eosinophilic Esophagitis Drug Sales by Application (2021-2026) & (K Units) Table 34. Global Eosinophilic Esophagitis Drug Sales by Application (2027-2032) & (K Units) Table 35. Global Eosinophilic Esophagitis Drug Sales Market Share by Application (2021-2026) Table 36. Global Eosinophilic Esophagitis Drug Sales Market Share by Application (2027-2032) Table 37. Global Eosinophilic Esophagitis Drug Revenue by Application 2021 VS 2025 VS 2032 (K Units) Table 38. Global Eosinophilic Esophagitis Drug Revenue by Application (2021-2026) & (K Units) Table 39. Global Eosinophilic Esophagitis Drug Revenue by Application (2027-2032) & (K Units) Table 40. Global Eosinophilic Esophagitis Drug Revenue Market Share by Application (2021-2026) Table 41. Global Eosinophilic Esophagitis Drug Revenue Market Share by Application (2027-2032) Table 42. Global Eosinophilic Esophagitis Drug Sales by Region: 2021 VS 2025 VS 2032 (K Units) Table 43. Global Eosinophilic Esophagitis Drug Sales by Region (2021-2026) & (K Units) Table 44. Global Eosinophilic Esophagitis Drug Sales Market Share by Region (2021-2026) Table 45. Global Eosinophilic Esophagitis Drug Sales Forecasted by Region (2027-2032) & (K Units) Table 46. Global Eosinophilic Esophagitis Drug Sales Forecasted Market Share by Region (2027-2032) Table 47. North America Eosinophilic Esophagitis Drug Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (K Units) Table 48. North America Eosinophilic Esophagitis Drug Sales by Country (2021-2026) & (K Units) Table 49. North America Eosinophilic Esophagitis Drug Sales by Country (2027-2032) & (K Units) Table 50. Europe Eosinophilic Esophagitis Drug Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (K Units) Table 51. Europe Eosinophilic Esophagitis Drug Sales by Country (2021-2026) & (K Units) Table 52. Europe Eosinophilic Esophagitis Drug Sales by Country (2027-2032) & (K Units) Table 53. Asia Pacific Eosinophilic Esophagitis Drug Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (K Units) Table 54. Asia Pacific Eosinophilic Esophagitis Drug Sales by Country (2021-2026) & (K Units) Table 55. Asia Pacific Eosinophilic Esophagitis Drug Sales by Country (2027-2032) & (K Units) Table 56. South America, Middle East and Africa Eosinophilic Esophagitis Drug Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (K Units) Table 57. South America, Middle East and Africa Eosinophilic Esophagitis Drug Sales by Country (2021-2026) & (K Units) Table 58. South America, Middle East and Africa Eosinophilic Esophagitis Drug Sales by Country (2027-2032) & (K Units) Table 59. Global Eosinophilic Esophagitis Drug Revenue Grow Rate (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 60. Global Eosinophilic Esophagitis Drug Revenue by Region (2021-2026) & (US$ Million) Table 61. Global Eosinophilic Esophagitis Drug Revenue by Region (2027-2032) & (US$ Million) Table 62. Global Eosinophilic Esophagitis Drug Revenue Market Share by Region (2021-2026) Table 63. Global Eosinophilic Esophagitis Drug Revenue Market Share by Region (2027-2032) Table 64. AstraZeneca Company Information Table 65. AstraZeneca Business Overview Table 66. AstraZeneca Eosinophilic Esophagitis Drug Sales (K Units), Price (USD/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 67. AstraZeneca Eosinophilic Esophagitis Drug Product Portfolio Table 68. AstraZeneca Recent Development Table 69. GSK Company Information Table 70. GSK Business Overview Table 71. GSK Eosinophilic Esophagitis Drug Sales (K Units), Price (USD/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 72. GSK Eosinophilic Esophagitis Drug Product Portfolio Table 73. GSK Recent Development Table 74. Bayer Company Information Table 75. Bayer Business Overview Table 76. Bayer Eosinophilic Esophagitis Drug Sales (K Units), Price (USD/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 77. Bayer Eosinophilic Esophagitis Drug Product Portfolio Table 78. Bayer Recent Development Table 79. Adare Pharmaceuticals Company Information Table 80. Adare Pharmaceuticals Business Overview Table 81. Adare Pharmaceuticals Eosinophilic Esophagitis Drug Sales (K Units), Price (USD/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 82. Adare Pharmaceuticals Eosinophilic Esophagitis Drug Product Portfolio Table 83. Adare Pharmaceuticals Recent Development Table 84. DBV Technologies Company Information Table 85. DBV Technologies Business Overview Table 86. DBV Technologies Eosinophilic Esophagitis Drug Sales (K Units), Price (USD/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 87. DBV Technologies Eosinophilic Esophagitis Drug Product Portfolio Table 88. DBV Technologies Recent Development Table 89. Dr. Falk Pharma Company Information Table 90. Dr. Falk Pharma Business Overview Table 91. Dr. Falk Pharma Eosinophilic Esophagitis Drug Sales (K Units), Price (USD/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 92. Dr. Falk Pharma Eosinophilic Esophagitis Drug Product Portfolio Table 93. Dr. Falk Pharma Recent Development Table 94. Quorum Innovations Company Information Table 95. Quorum Innovations Business Overview Table 96. Quorum Innovations Eosinophilic Esophagitis Drug Sales (K Units), Price (USD/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 97. Quorum Innovations Eosinophilic Esophagitis Drug Product Portfolio Table 98. Quorum Innovations Recent Development Table 99. Takeda Company Information Table 100. Takeda Business Overview Table 101. Takeda Eosinophilic Esophagitis Drug Sales (K Units), Price (USD/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 102. Takeda Eosinophilic Esophagitis Drug Product Portfolio Table 103. Takeda Recent Development Table 104. Calypso Company Information Table 105. Calypso Business Overview Table 106. Calypso Eosinophilic Esophagitis Drug Sales (K Units), Price (USD/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 107. Calypso Eosinophilic Esophagitis Drug Product Portfolio Table 108. Calypso Recent Development Table 109. Celgene Company Information Table 110. Celgene Business Overview Table 111. Celgene Eosinophilic Esophagitis Drug Sales (K Units), Price (USD/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 112. Celgene Eosinophilic Esophagitis Drug Product Portfolio Table 113. Celgene Recent Development Table 114. Regeneron Company Information Table 115. Regeneron Business Overview Table 116. Regeneron Eosinophilic Esophagitis Drug Sales (K Units), Price (USD/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 117. Regeneron Eosinophilic Esophagitis Drug Product Portfolio Table 118. Regeneron Recent Development Table 119. Key Raw Materials Table 120. Raw Materials Key Suppliers Table 121. Eosinophilic Esophagitis Drug Distributors List Table 122. Eosinophilic Esophagitis Drug Customers List Table 123. Research Programs/Design for This Report Table 124. Authors List of This Report Table 125. Secondary Sources Table 126. Primary Sources List of Figures Figure 1. Eosinophilic Esophagitis Drug Product Image Figure 2. Global Eosinophilic Esophagitis Drug Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Eosinophilic Esophagitis Drug Market Size (2021-2032) & (US$ Million) Figure 4. Global Eosinophilic Esophagitis Drug Sales (2021-2032) & (K Units) Figure 5. Global Eosinophilic Esophagitis Drug Average Price (USD/Unit) & (2021-2032) Figure 6. Global Top 5 and 10 Eosinophilic Esophagitis Drug Players Market Share by Revenue in 2025 Figure 7. Manufacturers Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 8. Budesonide Image Figure 9. Fluticasone Image Figure 10. Others Image Figure 11. Global Eosinophilic Esophagitis Drug Sales by Type (2021 VS 2025 VS 2032) & (K Units) Figure 12. Global Eosinophilic Esophagitis Drug Sales Market Share 2021 VS 2025 VS 2032 Figure 13. Global Eosinophilic Esophagitis Drug Sales Market Share by Type (2021-2032) Figure 14. Global Eosinophilic Esophagitis Drug Revenue by Type (2021 VS 2025 VS 2032) & (K Units) Figure 15. Global Eosinophilic Esophagitis Drug Revenue Market Share 2021 VS 2025 VS 2032 Figure 16. Global Eosinophilic Esophagitis Drug Revenue Market Share by Type (2021-2032) Figure 17. Hospitals Image Figure 18. Clinics Image Figure 19. Drugstore Image Figure 20. Global Eosinophilic Esophagitis Drug Sales by Application (2021 VS 2025 VS 2032) & (K Units) Figure 21. Global Eosinophilic Esophagitis Drug Sales Market Share 2021 VS 2025 VS 2032 Figure 22. Global Eosinophilic Esophagitis Drug Sales Market Share by Application (2021-2032) Figure 23. Global Eosinophilic Esophagitis Drug Revenue by Application (2021 VS 2025 VS 2032) & (K Units) Figure 24. Global Eosinophilic Esophagitis Drug Revenue Market Share 2021 VS 2025 VS 2032 Figure 25. Global Eosinophilic Esophagitis Drug Revenue Market Share by Application (2021-2032) Figure 26. North America Eosinophilic Esophagitis Drug Sales and Growth Rate (2021-2032) & (K Units) Figure 27. North America Eosinophilic Esophagitis Drug Sales Market Share by Country (2021-2032) Figure 28. U.S. Eosinophilic Esophagitis Drug Sales and Growth Rate (2021-2032) & (K Units) Figure 29. Canada Eosinophilic Esophagitis Drug Sales and Growth Rate (2021-2032) & (K Units) Figure 30. Mexico Eosinophilic Esophagitis Drug Sales and Growth Rate (2021-2032) & (K Units) Figure 31. Europe Eosinophilic Esophagitis Drug Sales and Growth Rate (2021-2032) & (K Units) Figure 32. Europe Eosinophilic Esophagitis Drug Sales Market Share by Country (2021-2032) Figure 33. Germany Eosinophilic Esophagitis Drug Sales and Growth Rate (2021-2032) & (K Units) Figure 34. France Eosinophilic Esophagitis Drug Sales and Growth Rate (2021-2032) & (K Units) Figure 35. U.K. Eosinophilic Esophagitis Drug Sales and Growth Rate (2021-2032) & (K Units) Figure 36. Italy Eosinophilic Esophagitis Drug Sales and Growth Rate (2021-2032) & (K Units) Figure 37. Netherlands Eosinophilic Esophagitis Drug Sales and Growth Rate (2021-2032) & (K Units) Figure 38. Asia Pacific Eosinophilic Esophagitis Drug Sales and Growth Rate (2021-2032) & (K Units) Figure 39. Asia Pacific Eosinophilic Esophagitis Drug Sales Market Share by Country (2021-2032) Figure 40. China Eosinophilic Esophagitis Drug Sales and Growth Rate (2021-2032) & (K Units) Figure 41. Japan Eosinophilic Esophagitis Drug Sales and Growth Rate (2021-2032) & (K Units) Figure 42. South Korea Eosinophilic Esophagitis Drug Sales and Growth Rate (2021-2032) & (K Units) Figure 43. Southeast Asia Eosinophilic Esophagitis Drug Sales and Growth Rate (2021-2032) & (K Units) Figure 44. India Eosinophilic Esophagitis Drug Sales and Growth Rate (2021-2032) & (K Units) Figure 45. Australia Eosinophilic Esophagitis Drug Sales and Growth Rate (2021-2032) & (K Units) Figure 46. South America, Middle East and Africa Eosinophilic Esophagitis Drug Sales and Growth Rate (2021-2032) & (K Units) Figure 47. South America, Middle East and Africa Eosinophilic Esophagitis Drug Sales Market Share by Country (2021-2032) Figure 48. Brazil Eosinophilic Esophagitis Drug Sales and Growth Rate (2021-2032) & (K Units) Figure 49. South Africa Eosinophilic Esophagitis Drug Sales and Growth Rate (2021-2032) & (K Units) Figure 50. Saudi Arabia Eosinophilic Esophagitis Drug Sales and Growth Rate (2021-2032) & (K Units) Figure 51. Turkey Eosinophilic Esophagitis Drug Sales and Growth Rate (2021-2032) & (K Units) Figure 52. Argentina Eosinophilic Esophagitis Drug Sales and Growth Rate (2021-2032) & (K Units) Figure 53. UAE Eosinophilic Esophagitis Drug Sales and Growth Rate (2021-2032) & (K Units) Figure 54. Egypt Eosinophilic Esophagitis Drug Sales and Growth Rate (2021-2032) & (K Units) Figure 55. Chile Eosinophilic Esophagitis Drug Sales and Growth Rate (2021-2032) & (K Units) Figure 56. Global Eosinophilic Esophagitis Drug Revenue (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 57. Global Eosinophilic Esophagitis Drug Revenue Market Share by Region in Percentage: 2025 Versus 2032 Figure 58. North America Eosinophilic Esophagitis Drug Revenue (2021-2032) & (US$ Million) Figure 59. North America Eosinophilic Esophagitis Drug Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 60. Europe Eosinophilic Esophagitis Drug Revenue (2021-2032) & (US$ Million) Figure 61. Europe Eosinophilic Esophagitis Drug Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 62. Asia-Pacific Eosinophilic Esophagitis Drug Revenue (2021-2032) & (US$ Million) Figure 63. Asia-Pacific Eosinophilic Esophagitis Drug Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 64. South America, Middle East and Africa Eosinophilic Esophagitis Drug Revenue (2021-2032) & (US$ Million) Figure 65. South America, Middle East and Africa Eosinophilic Esophagitis Drug Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 66. Eosinophilic Esophagitis Drug Value Chain Figure 67. Manufacturing Cost Structure Figure 68. Eosinophilic Esophagitis Drug Production Mode & Process Figure 69. Direct Comparison with Distribution Share Figure 70. Distributors Profiles Figure 71. Years Considered Figure 72. Research Process Figure 73. Key Executives Interviewed

Scope & coverage.

Types
  • Budesonide
  • Fluticasone
  • Others
Applications
  • Hospitals
  • Clinics
  • Drugstore
Companies covered
  • AstraZeneca
  • GSK
  • Bayer
  • Adare Pharmaceuticals
  • DBV Technologies
  • Dr. Falk Pharma
  • Quorum Innovations
  • Takeda
  • Calypso
  • Celgene
  • Regeneron

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Eosinophilic Esophagitis Drug Market Size, 2021 VS 2025 VS 2032
  3. 1.3 Global Eosinophilic Esophagitis Drug Market Size Estimates and Forecasts (2021-2032)
  4. 1.4 Global Eosinophilic Esophagitis Drug Sales Estimates and Forecasts (2021-2032)
  5. 1.5 Global Eosinophilic Esophagitis Drug Market Average Price (2021-2032)
  6. 1.6 Assumptions and Limitations
  7. 1.7 Study Goals and Objectives
2 Global Eosinophilic Esophagitis Drug Market Dynamics
  1. 2.1 Eosinophilic Esophagitis Drug Industry Trends
  2. 2.2 Eosinophilic Esophagitis Drug Industry Drivers
  3. 2.3 Eosinophilic Esophagitis Drug Industry Opportunities and Challenges
  4. 2.4 Eosinophilic Esophagitis Drug Industry Restraints
3 Eosinophilic Esophagitis Drug Market by Manufacturers
  1. 3.1 Global Eosinophilic Esophagitis Drug Revenue by Manufacturers (2021-2026)
  2. 3.2 Global Eosinophilic Esophagitis Drug Sales by Manufacturers (2021-2026)
  3. 3.3 Global Eosinophilic Esophagitis Drug Average Sales Price by Manufacturers (2021-2026)
  4. 3.4 Global Eosinophilic Esophagitis Drug Industry Manufacturers Ranking, 2024 VS 2025 VS 2026
  5. 3.5 Global Eosinophilic Esophagitis Drug Key Manufacturers Manufacturing Sites & Headquarters
  6. 3.6 Global Eosinophilic Esophagitis Drug Manufacturers, Product Type & Application
  7. 3.7 Global Eosinophilic Esophagitis Drug Manufacturers Establishment Date
  8. 3.8 Market Competitive Analysis
  9. 3.8.1 Global Eosinophilic Esophagitis Drug Market CR5 and HHI
  10. 3.8.2 Global Top 5 and 10 Eosinophilic Esophagitis Drug Players Market Share by Revenue in 2025
  11. 3.8.3 2025 Eosinophilic Esophagitis Drug Tier 1, Tier 2, and Tier 3
4 Eosinophilic Esophagitis Drug Market by Type
  1. 4.1 Eosinophilic Esophagitis Drug Type Introduction
  2. 4.1.1 Budesonide
  3. 4.1.2 Fluticasone
  4. 4.1.3 Others
  5. 4.2 Global Eosinophilic Esophagitis Drug Sales by Type
  6. 4.2.1 Global Eosinophilic Esophagitis Drug Sales by Type (2021 VS 2025 VS 2032)
  7. 4.2.2 Global Eosinophilic Esophagitis Drug Sales by Type (2021-2032)
  8. 4.2.3 Global Eosinophilic Esophagitis Drug Sales Market Share by Type (2021-2032)
  9. 4.3 Global Eosinophilic Esophagitis Drug Revenue by Type
  10. 4.3.1 Global Eosinophilic Esophagitis Drug Revenue by Type (2021 VS 2025 VS 2032)
  11. 4.3.2 Global Eosinophilic Esophagitis Drug Revenue by Type (2021-2032)
  12. 4.3.3 Global Eosinophilic Esophagitis Drug Revenue Market Share by Type (2021-2032)
5 Eosinophilic Esophagitis Drug Market by Application
  1. 5.1 Eosinophilic Esophagitis Drug Application Introduction
  2. 5.1.1 Hospitals
  3. 5.1.2 Clinics
  4. 5.1.3 Drugstore
  5. 5.2 Global Eosinophilic Esophagitis Drug Sales by Application
  6. 5.2.1 Global Eosinophilic Esophagitis Drug Sales by Application (2021 VS 2025 VS 2032)
  7. 5.2.2 Global Eosinophilic Esophagitis Drug Sales by Application (2021-2032)
  8. 5.2.3 Global Eosinophilic Esophagitis Drug Sales Market Share by Application (2021-2032)
  9. 5.3 Global Eosinophilic Esophagitis Drug Revenue by Application
  10. 5.3.1 Global Eosinophilic Esophagitis Drug Revenue by Application (2021 VS 2025 VS 2032)
  11. 5.3.2 Global Eosinophilic Esophagitis Drug Revenue by Application (2021-2032)
  12. 5.3.3 Global Eosinophilic Esophagitis Drug Revenue Market Share by Application (2021-2032)
6 Global Eosinophilic Esophagitis Drug Sales by Region
  1. 6.1 Global Eosinophilic Esophagitis Drug Sales by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Eosinophilic Esophagitis Drug Sales by Region (2021-2032)
  3. 6.2.1 Global Eosinophilic Esophagitis Drug Sales by Region (2021-2026)
  4. 6.2.2 Global Eosinophilic Esophagitis Drug Sales Forecasted by Region (2027-2032)
  5. 6.3 North America
  6. 6.3.1 North America Eosinophilic Esophagitis Drug Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  7. 6.3.2 North America Eosinophilic Esophagitis Drug Sales by Country (2021-2032)
  8. 6.3.3 U.S.
  9. 6.3.4 Canada
  10. 6.3.5 Mexico
  11. 6.4 Europe
  12. 6.4.1 Europe Eosinophilic Esophagitis Drug Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  13. 6.4.2 Europe Eosinophilic Esophagitis Drug Sales by Country (2021-2032)
  14. 6.4.3 Germany
  15. 6.4.4 France
  16. 6.4.5 U.K.
  17. 6.4.6 Italy
  18. 6.4.7 Netherlands
  19. 6.5 Asia Pacific
  20. 6.5.1 Asia Pacific Eosinophilic Esophagitis Drug Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  21. 6.5.2 Asia Pacific Eosinophilic Esophagitis Drug Sales by Country (2021-2032)
  22. 6.5.3 China
  23. 6.5.4 Japan
  24. 6.5.5 South Korea
  25. 6.5.6 Southeast Asia
  26. 6.5.7 India
  27. 6.5.8 Australia
  28. 6.6 South America, Middle East and Africa
  29. 6.6.1 South America, Middle East and Africa Eosinophilic Esophagitis Drug Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  30. 6.6.2 South America, Middle East and Africa Eosinophilic Esophagitis Drug Sales by Country (2021-2032)
  31. 6.6.3 Brazil
  32. 6.6.4 South Africa
  33. 6.6.5 Saudi Arabia
  34. 6.6.6 Turkey
  35. 6.6.6 Argentina
  36. 6.6.6 UAE
  37. 6.6.6 Egypt
  38. 6.6.6 Chile
7 Global Eosinophilic Esophagitis Drug Revenue by Region
  1. 7.1 Global Eosinophilic Esophagitis Drug Revenue by Region
  2. 7.1.1 Global Eosinophilic Esophagitis Drug Revenue by Region: 2021 VS 2025 VS 2032
  3. 7.1.2 Global Eosinophilic Esophagitis Drug Revenue by Region (2021-2026)
  4. 7.1.3 Global Eosinophilic Esophagitis Drug Revenue by Region (2027-2032)
  5. 7.1.4 Global Eosinophilic Esophagitis Drug Revenue Market Share by Region (2021-2032)
  6. 7.2 North America
  7. 7.2.1 North America Eosinophilic Esophagitis Drug Revenue (2021-2032)
  8. 7.2.2 North America Eosinophilic Esophagitis Drug Revenue Share by Country: 2021 VS 2025 VS 2032
  9. 7.3 Europe
  10. 7.3.1 Europe Eosinophilic Esophagitis Drug Revenue (2021-2032)
  11. 7.3.2 Europe Eosinophilic Esophagitis Drug Revenue Share by Country: 2021 VS 2025 VS 2032
  12. 7.4 Asia-Pacific
  13. 7.4.1 Asia-Pacific Eosinophilic Esophagitis Drug Revenue (2021-2032)
  14. 7.4.2 Asia-Pacific Eosinophilic Esophagitis Drug Revenue Share by Country: 2021 VS 2025 VS 2032
  15. 7.5 South America, Middle East and Africa
  16. 7.5.1 South America, Middle East and Africa Eosinophilic Esophagitis Drug Revenue (2021-2032)
  17. 7.5.2 South America, Middle East and Africa Eosinophilic Esophagitis Drug Revenue Share by Country: 2021 VS 2025 VS 2032
8 Company Profiles
  1. 8.1 AstraZeneca
  2. 8.1.1 AstraZeneca Company Information
  3. 8.1.2 AstraZeneca Business Overview
  4. 8.1.3 AstraZeneca Eosinophilic Esophagitis Drug Sales, Price, Revenue and Gross Margin (2021-2026)
  5. 8.1.4 AstraZeneca Eosinophilic Esophagitis Drug Product Portfolio
  6. 8.1.5 AstraZeneca Recent Developments
  7. 8.2 GSK
  8. 8.2.1 GSK Company Information
  9. 8.2.2 GSK Business Overview
  10. 8.2.3 GSK Eosinophilic Esophagitis Drug Sales, Price, Revenue and Gross Margin (2021-2026)
  11. 8.2.4 GSK Eosinophilic Esophagitis Drug Product Portfolio
  12. 8.2.5 GSK Recent Developments
  13. 8.3 Bayer
  14. 8.3.1 Bayer Company Information
  15. 8.3.2 Bayer Business Overview
  16. 8.3.3 Bayer Eosinophilic Esophagitis Drug Sales, Price, Revenue and Gross Margin (2021-2026)
  17. 8.3.4 Bayer Eosinophilic Esophagitis Drug Product Portfolio
  18. 8.3.5 Bayer Recent Developments
  19. 8.4 Adare Pharmaceuticals
  20. 8.4.1 Adare Pharmaceuticals Company Information
  21. 8.4.2 Adare Pharmaceuticals Business Overview
  22. 8.4.3 Adare Pharmaceuticals Eosinophilic Esophagitis Drug Sales, Price, Revenue and Gross Margin (2021-2026)
  23. 8.4.4 Adare Pharmaceuticals Eosinophilic Esophagitis Drug Product Portfolio
  24. 8.4.5 Adare Pharmaceuticals Recent Developments
  25. 8.5 DBV Technologies
  26. 8.5.1 DBV Technologies Company Information
  27. 8.5.2 DBV Technologies Business Overview
  28. 8.5.3 DBV Technologies Eosinophilic Esophagitis Drug Sales, Price, Revenue and Gross Margin (2021-2026)
  29. 8.5.4 DBV Technologies Eosinophilic Esophagitis Drug Product Portfolio
  30. 8.5.5 DBV Technologies Recent Developments
  31. 8.6 Dr. Falk Pharma
  32. 8.6.1 Dr. Falk Pharma Company Information
  33. 8.6.2 Dr. Falk Pharma Business Overview
  34. 8.6.3 Dr. Falk Pharma Eosinophilic Esophagitis Drug Sales, Price, Revenue and Gross Margin (2021-2026)
  35. 8.6.4 Dr. Falk Pharma Eosinophilic Esophagitis Drug Product Portfolio
  36. 8.6.5 Dr. Falk Pharma Recent Developments
  37. 8.7 Quorum Innovations
  38. 8.7.1 Quorum Innovations Company Information
  39. 8.7.2 Quorum Innovations Business Overview
  40. 8.7.3 Quorum Innovations Eosinophilic Esophagitis Drug Sales, Price, Revenue and Gross Margin (2021-2026)
  41. 8.7.4 Quorum Innovations Eosinophilic Esophagitis Drug Product Portfolio
  42. 8.7.5 Quorum Innovations Recent Developments
  43. 8.8 Takeda
  44. 8.8.1 Takeda Company Information
  45. 8.8.2 Takeda Business Overview
  46. 8.8.3 Takeda Eosinophilic Esophagitis Drug Sales, Price, Revenue and Gross Margin (2021-2026)
  47. 8.8.4 Takeda Eosinophilic Esophagitis Drug Product Portfolio
  48. 8.8.5 Takeda Recent Developments
  49. 8.9 Calypso
  50. 8.9.1 Calypso Company Information
  51. 8.9.2 Calypso Business Overview
  52. 8.9.3 Calypso Eosinophilic Esophagitis Drug Sales, Price, Revenue and Gross Margin (2021-2026)
  53. 8.9.4 Calypso Eosinophilic Esophagitis Drug Product Portfolio
  54. 8.9.5 Calypso Recent Developments
  55. 8.10 Celgene
  56. 8.10.1 Celgene Company Information
  57. 8.10.2 Celgene Business Overview
  58. 8.10.3 Celgene Eosinophilic Esophagitis Drug Sales, Price, Revenue and Gross Margin (2021-2026)
  59. 8.10.4 Celgene Eosinophilic Esophagitis Drug Product Portfolio
  60. 8.10.5 Celgene Recent Developments
  61. 8.11 Regeneron
  62. 8.11.1 Regeneron Company Information
  63. 8.11.2 Regeneron Business Overview
  64. 8.11.3 Regeneron Eosinophilic Esophagitis Drug Sales, Price, Revenue and Gross Margin (2021-2026)
  65. 8.11.4 Regeneron Eosinophilic Esophagitis Drug Product Portfolio
  66. 8.11.5 Regeneron Recent Developments
9 Value Chain and Sales Channels Analysis
  1. 9.1 Eosinophilic Esophagitis Drug Value Chain Analysis
  2. 9.1.1 Eosinophilic Esophagitis Drug Key Raw Materials
  3. 9.1.2 Raw Materials Key Suppliers
  4. 9.1.3 Manufacturing Cost Structure
  5. 9.1.4 Eosinophilic Esophagitis Drug Production Mode & Process
  6. 9.2 Eosinophilic Esophagitis Drug Sales Channels Analysis
  7. 9.2.1 Direct Comparison with Distribution Share
  8. 9.2.2 Eosinophilic Esophagitis Drug Distributors
  9. 9.2.3 Eosinophilic Esophagitis Drug Customers
10 Concluding Insights
    11 Appendix
    1. 11.1 Reasons for Doing This Study
    2. 11.2 Research Methodology
    3. 11.3 Research Process
    4. 11.4 Authors List of This Report
    5. 11.5 Data Source
    6. 11.5.1 Secondary Sources
    7. 11.5.2 Primary Sources
    8. 11.6 Disclaimer

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $3,950USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research, Inc.
    Talk to an analyst